Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FWPAY Forward Pharma A/S	$300.00	$424.38	$1.43 ▼ $5.33	$6M	-42.67	7 shs	11 shs
IRD Opus Genetics	$0.98 -4.3%	$0.96	$0.65 ▼ $1.75	$58.27M	N/A	525,554 shs	783,289 shs
LEXX Lexaria Bioscience	$0.85 -1.2%	$1.07	$0.82 ▼ $4.38	$14.91M	0.84	147,832 shs	62,712 shs
TENX Tenax Therapeutics	$5.85 -2.0%	$5.82	$2.80 ▼ $7.89	$24.28M	1.61	161,673 shs	8,091 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FWPAY Forward Pharma A/S	0.00%	0.00%	0.00%	0.00%	0.00%
IRD Opus Genetics	0.00%	+2.79%	-2.66%	-0.53%	+97,659,900.00%
LEXX Lexaria Bioscience	0.00%	-11.56%	-15.94%	-50.35%	-69.46%
TENX Tenax Therapeutics	0.00%	+1.04%	-6.40%	-10.69%	+94.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FWPAY Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	1.8084 of 5 stars	3.5	0.0	0.0	0.0	2.4	0.0	0.6
LEXX Lexaria Bioscience	3.2172 of 5 stars	3.5	4.0	0.0	0.0	3.1	1.7	0.6
TENX Tenax Therapeutics	1.4081 of 5 stars	3.6	0.0	0.0	0.0	2.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FWPAY Forward Pharma A/S	0.00	N/A	N/A	N/A
IRD Opus Genetics	3.00	Buy	$7.33	650.90% Upside
LEXX Lexaria Bioscience	3.00	Buy	$7.00	724.50% Upside
TENX Tenax Therapeutics	3.25	Buy	$17.50	199.15% Upside

Current Analyst Ratings Breakdown

Latest FWPAY, IRD, TENX, and LEXX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/15/2025	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
4/11/2025	IRD Opus Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
4/1/2025	IRD Opus Genetics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $8.00
4/1/2025	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FWPAY Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	$13.65M	4.27	N/A	N/A	$0.21 per share	4.65
LEXX Lexaria Bioscience	$460K	32.41	N/A	N/A	$0.48 per share	1.77
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$26.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FWPAY Forward Pharma A/S	-$1.89M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	-$57.53M	-$2.10	N/A	N/A	N/A	-429.42%	-283.28%	-144.32%	8/12/2025 (Estimated)
LEXX Lexaria Bioscience	-$5.80M	-$0.59	N/A	N/A	N/A	-1,784.03%	-111.84%	-100.48%	7/11/2025 (Estimated)
TENX Tenax Therapeutics	-$17.60M	-$2.48	N/A	N/A	N/A	N/A	-31.51%	-30.35%	8/12/2025 (Estimated)

Latest FWPAY, IRD, TENX, and LEXX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/11/2025	N/A	LEXX Lexaria Bioscience	-$0.15	N/A	N/A	N/A	$0.17 million	N/A
5/15/2025	Q1 2025	IRD Opus Genetics	-$0.34	-$0.32	+$0.02	-$0.24	$4.00 million	$4.30 million
5/14/2025	Q1 2025	TENX Tenax Therapeutics	-$0.48	-$0.28	+$0.20	-$0.28	N/A	N/A
4/14/2025	Q2 2025	LEXX Lexaria Bioscience	-$0.16	-$0.15	+$0.01	-$0.15	$0.14 million	$0.17 million
3/31/2025	Q4 2024	IRD Opus Genetics	-$0.34	-$1.27	-$0.93	-$1.27	$11.10 million	$3.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FWPAY Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FWPAY Forward Pharma A/S	N/A	N/A	N/A
IRD Opus Genetics	N/A	1.98	1.98
LEXX Lexaria Bioscience	N/A	4.24	4.24
TENX Tenax Therapeutics	N/A	40.48	40.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FWPAY Forward Pharma A/S	2.63%
IRD Opus Genetics	14.97%
LEXX Lexaria Bioscience	13.06%
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
FWPAY Forward Pharma A/S	71.47%
IRD Opus Genetics	6.60%
LEXX Lexaria Bioscience	26.40%
TENX Tenax Therapeutics	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FWPAY Forward Pharma A/S	N/A	20,000	7,000	Not Optionable
IRD Opus Genetics	14	59.66 million	55.72 million	N/A
LEXX Lexaria Bioscience	7	17.56 million	12.92 million	Not Optionable
TENX Tenax Therapeutics	9	4.15 million	4.00 million	Not Optionable

FWPAY, IRD, TENX, and LEXX Headlines

Recent News About These Companies

TENX Tenax Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened

June 24, 2025 | americanbankingnews.com

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | globenewswire.com

Tenax Therapeutics Inc.

May 9, 2025 | barrons.com

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

April 16, 2025 | seekingalpha.com

Tenax Therapeutics files to sell 4.14M shares of common stock for holders

April 16, 2025 | markets.businessinsider.com

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics (TENX) Gets a Buy from William Blair

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics: Q4 Earnings Snapshot

March 25, 2025 | timesunion.comT

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 25, 2025 | globenewswire.com

Tenax Therapeutics Inc TENX

March 14, 2025 | morningstar.comM

Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)

March 6, 2025 | markets.businessinsider.com

Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103

March 5, 2025 | markets.businessinsider.com

Tenax Therapeutics prices 378,346 shares at $6.04 in private placement

March 5, 2025 | markets.businessinsider.com

Tenax Therapeutics Announces $25 Million Private Placement

March 5, 2025 | globenewswire.com

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

March 5, 2025 | globenewswire.com

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

March 3, 2025 | markets.businessinsider.com

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

January 31, 2025 | globenewswire.com

Tenax Therapeutics, Inc. Common Stock (TENX) Insider Activity

January 28, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
Microsoft Stock Holds Steady as AI Drives Workforce Shift
By Chris Markoch | June 23, 2025
View Microsoft Stock Holds Steady as AI Drives Workforce Shift
Regional Bank Buybacks: 5 Institutions Making Big Moves
By Leo Miller | June 24, 2025
View Regional Bank Buybacks: 5 Institutions Making Big Moves

FWPAY, IRD, TENX, and LEXX Company Descriptions

Forward Pharma A/S NASDAQ:FWPAY

Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark.

Opus Genetics NASDAQ:IRD

$0.98 -0.04 (-4.25%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.94 -0.04 (-3.95%)

As of 05:21 AM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Lexaria Bioscience NASDAQ:LEXX

$0.85 -0.01 (-1.23%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.90 +0.05 (+5.42%)

As of 04:08 AM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Tenax Therapeutics NASDAQ:TENX

$5.85 -0.12 (-2.01%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$6.10 +0.25 (+4.27%)

As of 04:00 AM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time